Drug Profile
Research programme: recombinant human fibrinogen - Pharming
Alternative Names: rhFIBLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Pharming Group NV
- Class Acute-phase proteins; Blood coagulation factors; Protein precursors; Recombinant proteins
- Mechanism of Action Fibrinogen replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Afibrinogenaemia
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for research development in Afibrinogenaemia in Netherlands (Parenteral)
- 31 Dec 2008 Early research is ongoing in the Netherlands
- 16 Oct 2007 Early research in Afibrinogenaemia in the Netherlands (Parenteral)